本文選題：地西他濱 + CAG方案��； 參考：《中國實驗血液學(xué)雜志》2017年05期

【摘要】：目的:通過回顧性分析探討低劑量地西他濱序貫CAG方案治療骨髓增生異常綜合征-難治性貧血伴有原始細胞過多(MDS-RAEB)的臨床療效。方法:將我院收治的接受低劑量地西他濱序貫CAG方案治療的36例MDSRAEB患者,納入地西他濱序貫CAG組;同期將單用地西他濱治療的M DS-RAEB 40例患者作為對照,比較2組患者臨床特征、療效及不良反應(yīng)等。結(jié)果:序貫CAG組總有效率(ORR)[完全緩解(CR)+部分緩解(PR)+血液學(xué)改善(HI)]為83.3%(30/36),明顯高于單用地西他濱ORR 62.5%(25/40)(P=0.043),2組不良反應(yīng)比較無顯著差別。地西他濱序貫CAG組最常見的不良反應(yīng)為3度以上的血細胞減少和感染,在治療早期(第1-2療程)比較常見,治療有效后上述不良反應(yīng)逐漸減少,其他非血液學(xué)不良反應(yīng)少見。結(jié)論:地西他濱序貫CAG方案治療MDS-RAEB比單用地西他濱療效更確切,此方案對不適合行造血干細胞移植的患者可能有重要的臨床價值。
[Abstract]:Objective: To explore the clinical effect of low dose of the sequential CAG regimen for the treatment of myelodysplastic syndrome, refractory anemia and primitive cell overabundance (MDS-RAEB) by retrospective analysis. Methods: 36 cases of MDSRAEB patients treated in our hospital were treated with low dose of West itabine sequential CAG regimen and included in the sequential CAG group. 40 patients with M DS-RAEB treated with single use of Western itabine as control were compared. The clinical features, efficacy and adverse reactions of the 2 groups were compared. Results: the total effective rate of the sequential CAG group (ORR) [complete remission (CR) + partial remission (PR) + hematological improvement (HI)] was 83.3% (30/36), obviously higher than the ORR 62.5% (25/40) (P=0.043) of single use, 2 groups of adverse reactions. There is no significant difference. The most common adverse reaction in the CAG group is more than 3 degrees of hemocyte reduction and infection. In the early treatment (the 1-2 course of treatment), the most common adverse reaction is more common. After the treatment is effective, the aforesaid adverse reactions are gradually reduced and other non hematological adverse reactions are rare. Conclusion: the sequential CAG regimen of the sahitabine is used for the treatment of MDS-RAEB than the single use land. The efficacy of citabine is more accurate. This scheme may have important clinical value for patients who are not suitable for hematopoietic stem cell transplantation.
【作者單位】： 鄭州大學(xué)第一附屬醫(yī)院血液科;
【基金】：國家自然科學(xué)基金(U1504806) 河南省醫(yī)學(xué)科技攻關(guān)計劃項目(201403029)
【分類號】：R551.3;R556

【相似文獻】

相關(guān)期刊論文 前10條

1 王晶超;李梅君;;地西他濱治療骨髓增生異常綜合征的研究進展[J];中華實用診斷與治療雜志;2008年08期

2 李娟;嚴魯萍;許亞梅;;地西他濱配合中藥治療骨髓增生異常綜合征1例[J];貴陽中醫(yī)學(xué)院學(xué)報;2010年02期

3 高沖;陳寶安;劉苒;徐昕;丁家華;王駿;程堅;趙剛;余正平;宋慧慧;鮑文;;地西他濱治療骨髓增生異常綜合征一例報告[J];現(xiàn)代醫(yī)學(xué);2010年02期

4 宋慧慧;陳寶安;劉苒;高沖;丁家華;孫耘玉;王駿;程堅;趙剛;余正平;鮑文;;地西他濱3d方案治療骨髓增生異常綜合征療效討論附兩例病例報道[J];東南大學(xué)學(xué)報(醫(yī)學(xué)版);2011年03期

5 譚振清;羅自勉;周新伏;;低劑量地西他濱治療骨髓增生異常綜合征的療效分析[J];現(xiàn)代腫瘤醫(yī)學(xué);2012年08期

6 李倩;鄭智茵;;地西他濱治療中危骨髓增生異常綜合征2例并文獻復(fù)習(xí)[J];浙江中西醫(yī)結(jié)合雜志;2013年12期

7 朱小勤;邱仲川;陳s，

本文編號：2029940